The 10,000-Woman Milestone: What the Direct-to-Consumer Ultrasound Boom Reveals

TAMPA BAY, Fla. – November 10, 2026 – HerScan, a national provider of mobile breast ultrasound screenings, announced today that it screened 10,000 women across the United States during Breast Cancer Awareness Month. Behind this October milestone lies a much larger story about the evolving landscape of women's health, the limitations of standard mammography, and the booming market for direct-to-consumer medical services.

The company, which has performed supplemental breast ultrasound screenings for more than 300,000 women since its inception, utilizes community-based pop-up events to bypass traditional outpatient clinical imaging centers. By bringing certified female sonographers and remote board-certified radiologists directly to local venues, the organization is capitalizing on a growing consumer demand for proactive health data.

“Awareness matters when it leads to action. This October, 10,000 women made time for their breast health with HerScan,” said CiCi McMullen, CEO of the mobile screening provider. “Behind that number are individual women with busy lives, families, careers, and people counting on them. We’re proud they chose us to be part of their care.”

Yet, as tens of thousands of women open their wallets for these independent screenings, the medical community remains divided. The surge in direct-access imaging highlights a critical intersection of patient empowerment, systemic healthcare gaps, and the clinical dilemma of overdiagnosis.

Bridging the Density Gap Outside the Clinic

The primary driver behind the demand for supplemental breast imaging is breast density. Nearly half of all women in the United States have dense breast tissue, which appears white on a standard mammogram—the exact same color as tumors. This masking effect can significantly reduce the sensitivity of mammography, sometimes to as low as fifty percent.

Recent federal rules mandating that healthcare facilities notify patients about their breast density have successfully raised public awareness. However, this awareness has also created a bottleneck. Women are now informed that their mammograms might not be sufficient, but securing an insurance-covered supplemental ultrasound or MRI within a traditional healthcare network can be an arduous process of referrals, long wait times, and strict medical necessity criteria.

Direct-to-consumer models step directly into this void. Operating outside the traditional insurance framework, the service offers transparent, upfront pricing—typically $295, or $325 in states like California and New York. The fee covers a bilateral breast and axilla scan, radiologist interpretation, and online access to the results.

For many women, the out-of-pocket cost is a worthwhile trade-off for convenience and peace of mind. There are no physician orders required, no battles with insurance pre-authorizations, and no navigating the scheduling labyrinth of local hospital systems.

“We don’t want women to close out October with breast screening still on their to-do list,” McMullen added in the announcement. “Our message is simple: make the appointment, make the time, and give your breast health the attention it deserves. That commitment matters every month of the year.”

The Clinical Dilemma: Detection Versus False Alarms

While the accessibility of community-based screening is undeniable, the clinical implications are hotly debated among oncology and radiology associations. The American College of Radiology (ACR) and the Society of Breast Imaging (SBI) both acknowledge that adjunctive ultrasonography can significantly increase cancer detection rates in women with dense breasts. Studies indicate that adding ultrasound to mammography can increase detection by up to 96 percent in this specific demographic, finding small, invasive, node-negative cancers that traditional screening misses.

However, this heightened sensitivity comes with a steep clinical cost: an astronomical rate of false positives.

Breast ultrasound is highly operator-dependent and exceptionally sensitive, meaning it flags many benign cysts and fibroadenomas as suspicious. According to clinical data, between 92 and 97 percent of abnormal ultrasound results in randomized controlled trials are ultimately false positives. For every 1,000 women screened, ultrasound can produce dozens of additional false-positive recalls and unnecessary biopsies.

Because of this, the U.S. Preventive Services Task Force (USPSTF) does not routinely recommend supplemental ultrasound for average-risk women, and the ACR warns against its routine use for women with dense breasts who lack other high-risk factors.

One independent breast surgical oncologist, speaking on the condition of anonymity, noted the downstream effects of these independent screenings. "We frequently see patients who come into our clinic terrified because a direct-to-consumer ultrasound flagged a lesion," the oncologist explained. "We then have to order a diagnostic mammogram, perform a targeted clinical ultrasound, and often do a biopsy, only to find it is completely benign. The financial and emotional toll on the patient is immense."

Indeed, the psychological impact of a false positive is a significant consideration. While short-term anxiety usually dissipates once a benign diagnosis is confirmed, the waiting period can be agonizing. Furthermore, the risk of overdiagnosis—identifying and treating low-grade lesions that would never have caused symptoms or threatened the patient's life—is amplified with widespread supplemental screening.

The Cost of Convenience and Fragmented Care

The financial model of direct-to-consumer screening also presents challenges for the broader healthcare ecosystem. Because these mobile providers do not accept Medicare, Medicaid, or private insurance, the upfront cost is entirely the patient's responsibility.

Interestingly, this aligns with recent shifts in federal healthcare coverage. In 2024, Medicare revised its coverage policies, no longer fully covering breast ultrasounds solely for dense tissue when a mammogram shows no abnormalities. Instead, Medicare now treats it as a diagnostic tool requiring medical necessity, often leaving patients with a copay. This tightening of traditional coverage makes the flat-fee, direct-access model increasingly attractive to consumers, despite the lack of insurance reimbursement.

However, the true cost of fragmented care emerges when an abnormality is actually found. In the direct-to-consumer model, patients receive their results via a secure online portal within five to seven business days. The interpreting board-certified radiologists are remote and unavailable for patient consultations.

If a scan reveals a suspicious lesion, the mobile provider's involvement effectively ends. The report simply recommends that the patient follow up with their primary care physician or a local breast center. This places the burden of care coordination squarely on the patient's shoulders. They must take their independent imaging report, navigate their way back into the traditional healthcare system, and convince their insurance provider to cover the subsequent diagnostic workup. This disjointed pathway can lead to delays in definitive diagnosis and treatment, negating some of the benefits of early, proactive screening.

Navigating the Future of Supplemental Screening

The 10,000 women screened this past October represent a clear signal: consumers are no longer willing to accept the limitations of standard mammography, especially when armed with knowledge about their own breast density. They are demanding more data about their bodies and are willing to circumvent the traditional medical establishment to get it.

As the industry evolves, technological advancements may help mitigate the current drawbacks of supplemental screening. Automated Breast Ultrasound (ABUS), for example, is emerging as a technology that can detect cancer at similar rates to handheld ultrasound but with significantly fewer false-positive initial assessments. If direct-to-consumer providers adopt these more advanced, less operator-dependent technologies, the clinical friction surrounding independent screening could decrease.

Until then, the boom in mobile breast ultrasounds serves as a stark reminder of the gaps in our current preventative care models. When traditional healthcare networks fail to provide accessible, timely, and comprehensive screening options for the millions of women with dense breast tissue, the free market will inevitably step in to provide a solution. The challenge for the medical community is not to dismiss these direct-to-consumer services, but to figure out how to integrate this consumer-driven data into a cohesive, evidence-based continuum of care that prioritizes both early detection and patient well-being.